YahooOctober 5, 2026 at 5:02 PM NY22 Days Ago
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets
Compugen (NASDAQ:CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research during a company update event. President and Chief Executive Officer Er
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
